

Special Issue

Metronomic Chemotherapy in Female Cancers

Message from the Guest Editor

We invite submissions for a Special Issue on "Metronomic Chemotherapy in Female Cancers" in Cancers journal. This issue will feature research on the efficacy, mechanisms, and clinical implications of metronomic chemotherapy in female malignancies. Topics include evaluation in breast, ovarian, and cervical cancers, mechanistic insights, clinical trials, combination therapies, and future directions. Submissions will undergo peer review. We welcome contributions from researchers, oncologists, and pharmacologists. Your insights will advance our understanding of metronomic chemotherapy in female cancers. For inquiries or assistance, please contact us. Thank you for your interest. Best regards.

Guest Editor

Prof. Dr. Luca Roncati

1. Department of Life Sciences, Health, and Health Care Professions, School of Medicine and Surgery, Link Campus University, Rome, Italy
2. Department of Women's Health, European Institute of Dermatology, Milan, Italy

Deadline for manuscript submissions

closed (14 February 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/231359

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)